# CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

> **NCT06212154** · PHASE1 · UNKNOWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 13 (estimated)

## Conditions studied

- Autoimmune Hemolytic Anemia
- CD19 CAR-T Cell Infusion

## Interventions

- **BIOLOGICAL:** ThisCART19A

## Key facts

- **NCT ID:** NCT06212154
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-20
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2024-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06212154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06212154, "CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06212154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*